In Seeking Focus, Ipsen Turns To Specialty Pharma Model
Executive Summary
Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.
You may also be interested in...
Inspiration’s Hemophilia Pact With Ipsen Gets Surprise Revamp
Inspiration Biopharma and hemophilia partner Ipsen have renegotiated their nearly three-year-old deal around two late-stage clinical assets. As part of the new deal, Ipsen has given up its option to buy Inspiration, providing the biotech with the opportunity – and the necessity – to find fresh financing from new backers in the coming months.
Financial Crunch Time For Inspiration As Hemophilia Pact With Ipsen Gets Surprise Revamp
Inspiration Biopharma and hemophilia partner Ipsen have renegotiated their nearly three-year-old deal around two late-stage clinical assets. As part of the new deal, Ipsen has given up its option to buy Inspiration, providing the biotech with the opportunity – and the necessity – to find fresh financing from new backers in the coming months.
Ipsen Moves Aggressively On U.S. Strategy, Builds Out Commercial and R&D Infrastructure
As part of an ongoing strategic reorganization, Ipsen announced the appointment of a nine-member U.S. leadership team to execute on the growth of its neurology and endocrinology franchises.